The SUMO pathway in pancreatic cancer: insights and inhibition

An urgent medical need to develop novel treatment strategies for patients with pancreatic ductal adenocarcinoma (PDAC) exists. However, despite various efforts in the histopathological and molecular subtyping of PDAC, novel targeted or specific therapies have not been established. Posttranslational...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneeweis, Christian, Hassan, Zonera, Schick, Markus, Keller, Ulrich, Schneider, Günter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851129/
https://www.ncbi.nlm.nih.gov/pubmed/33071285
http://dx.doi.org/10.1038/s41416-020-01119-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851129/
https://www.ncbi.nlm.nih.gov/pubmed/33071285
http://dx.doi.org/10.1038/s41416-020-01119-6

Ejemplares similares